ESSA Pharma Inc (EPIX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ESSA Pharma Inc (EPIX) has a cash flow conversion efficiency ratio of -0.039x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.20 Million) by net assets ($108.90 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see ESSA Pharma Inc (EPIX) market capitalisation for the company's overall valuation and market capitalisation.
ESSA Pharma Inc - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how ESSA Pharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
ESSA Pharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ESSA Pharma Inc ranked by their cash flow conversion efficiency. Explore ESSA Pharma Inc earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
RS Public Company Limited
BK:RS
|
-0.051x |
|
Zhuhai Sailong Pharmaceutical Co Ltd
SHE:002898
|
-0.076x |
|
Clinical Laserthermia Systems AB (publ)
ST:CLS-B
|
-0.106x |
|
Duketon Mining Ltd
AU:DKM
|
-0.008x |
|
Viking Mines Ltd
AU:VKA
|
-0.290x |
|
Infrared Cameras Holdings Inc
NASDAQ:MSAI
|
-0.070x |
|
Greentech Metals Ltd
AU:GRE
|
-0.056x |
|
Af Legal Group Ltd
AU:AFL
|
-0.015x |
Annual Cash Flow Conversion Efficiency for ESSA Pharma Inc (2012–2024)
The table below shows the annual cash flow conversion efficiency of ESSA Pharma Inc from 2012 to 2024. View ESSA Pharma Inc share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-09-30 | $124.61 Million | $-22.72 Million | -0.182x | -34.21% |
| 2023-09-30 | $145.63 Million | $-19.78 Million | -0.136x | +20.91% |
| 2022-09-30 | $167.12 Million | $-28.70 Million | -0.172x | -31.11% |
| 2021-09-30 | $194.01 Million | $-25.42 Million | -0.131x | +38.87% |
| 2020-09-30 | $79.24 Million | $-16.98 Million | -0.214x | +13.96% |
| 2019-09-30 | $49.18 Million | $-12.25 Million | -0.249x | +77.69% |
| 2018-09-30 | $9.15 Million | $-10.22 Million | -1.116x | -127.50% |
| 2017-09-30 | $-4.27 Million | $-17.35 Million | 4.061x | -85.75% |
| 2016-09-30 | $-537.00K | $-15.30 Million | 28.493x | +1125.81% |
| 2015-09-30 | $4.43 Million | $-12.30 Million | -2.778x | -163.48% |
| 2014-09-30 | $1.97 Million | $-2.08 Million | -1.054x | -66058.28% |
| 2013-09-30 | $479.04K | $-763.35 | -0.002x | +99.89% |
| 2012-09-30 | $1.31K | $-1.82K | -1.396x | -- |
About ESSA Pharma Inc
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company was incorporated in 2009 and is headquartered in Vancouver, Canada. As of October 9, 2025, ESSA Pharma Inc. operates as a subsidiary of Alexis Bio, Inc.